Patents by Inventor Jongwha Won

Jongwha Won has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CEACAM1 antibody and use thereof
    Patent number: 11332528
    Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 17, 2022
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: So-Young Eun, Miyoung Oh, Hye-Young Park, Mijung Lee, Aerin Yoon, Hye In Yum, Hyemi Nam, Eunhee Lee, Jongwha Won
  • Anti-mesothelin antibody and composition comprising the same
    Patent number: 10851175
    Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 1, 2020
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: Dong-Sik Kim, Eun Jung Song, Mijung Lee, Eun-Hee Lee, Miyoung Oh, Jae Chan Park, Kisu Kim, Sujeong Kim, Hyung-Kwon Lim, Kyuhyun Lee, Jongwha Won, Soongyu Choi, Young Seoub Park
  • Anti-glypican 3 antibody and pharmaceutical composition containing the same
    Patent number: 10752697
    Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 25, 2020
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Jae Chan Park, Kisu Kim, Mijung Lee, Eun-Hee Lee, Dong-Sik Kim, Eun Jung Song, Sujeong Kim, Hyung-Kwon Lim, Kyuhyun Lee, Jongwha Won, Soongyu Choi, Young Seoub Park
  • ANTI-CEACAM1 ANTIBODY AND USE THEREOF
    Publication number: 20200109196
    Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 9, 2020
    Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: So-Young EUN, Miyoung OH, Hye-Young PARK, Mijung LEE, Aerin YOON, Hye In YUM, Hyemi NAM, Eunhee LEE, Jongwha WON
  • NOVEL ANTI-GLYPICAN 3 ANTIBODY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
    Publication number: 20180346592
    Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.
    Type: Application
    Filed: October 27, 2016
    Publication date: December 6, 2018
    Inventors: Jae Chan PARK, Kisu KIM, Mijung LEE, Eun-Hee LEE, Dong-Sik KIM, Eun Jung SONG, Sujeong KIM, Hyung-Kwon LIM, Kyuhyun LEE, Jongwha WON, Soongyu CHOI, Young Seoub PARK
  • NOVEL ANTI-MESOTHELIN ANTIBODY AND COMPOSITION COMPRISING THE SAME
    Publication number: 20180346588
    Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.
    Type: Application
    Filed: September 23, 2016
    Publication date: December 6, 2018
    Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: Dong-Sik KIM, Eun Jung SONG, Mijung LEE, Eun-Hee LEE, Miyoung OH, Jae Chan PARK, Kisu KIM, Sujeong KIM, Hyung-Kwon LIM, Kyuhyun LEE, Jongwha WON, Soongyu CHOI, Young Seoub PARK
  • Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition
    Publication number: 20040082664
    Abstract: The present invention relates to derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition, more particularly the compounds of the present invention specifically inhibit the activation of T lymphocyte by src homology region 2(SH2) domain of T lymphocyte (lck), so that they can be used for the treatment, prevention and/or diagnosis of graft rejection, autoimmune diseases, inflammatory diseases, etc.
    Type: Application
    Filed: April 11, 2003
    Publication date: April 29, 2004
    Inventors: Jongwha Won, Keunhyeung Lee, Seehyoung Park, Sung-Joo Kim, Su-Young Yun, Mi-Ae Kang, Yun-Gyoung Hur, Jeehee Youn, Yungdae Yun, Doohong Park, Jaetaek Oh